Today’s news:
“Cambrian Biopharma today announced the closing of an oversubscribed Series C financing, which raised $100 million. Focused on developing therapeutics to extend healthspan, Cambrian is advancing an expansive diversified pipeline of scientific breakthroughs, each targeting a biological driver of aging that leads to disease. Their approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve overall quality of life as we age.
Age-related diseases account for more than two-thirds of all deaths worldwide, taking 41 million lives every year, or nearly one death every second. Existing approaches to these diseases are almost exclusively reactive – waiting for people to get sick and only then using the rapidly expanding knowledge of biology to try to treat very sick patients.
The company also announced the appointments of Paul Farr, former Allergan chief executive, and BridgeBio director Brent Saunders to its board of directors.”
• Bloomberg TV interview: “The Startup That May Hold the Key to Extending Human Life”
• CEO on twitter
• Company: www.CambrianBio.com
CONGRATS team Cambrian!
Leave a Reply